查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1607044

局部性腎小球硬化症市場：按藥物類別、階段、分銷管道、最終用戶分類 - 全球預測 2025-2030

Focal Segmental Glomerulosclerosis Market by Drug Class (Angiotensin Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Corticosteroids), Stage (Primary, Secondary), Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

局部節段性腎絲球硬化市場2023年估值為161.9億美元，預計2024年將達到174.1億美元，複合年成長率為7.83%，2030年將達27.4億美元，預計將達到5000兆美元。

局部節段性腎絲球硬化症 (FSGS) 是一種罕見的腎臟疾病，其特徵是部分腎小球出現疤痕，導致腎功能嚴重受損。市場的範圍和定義圍繞著製藥和醫療保健領域，其中免疫抑制劑、ACE抑制劑和新生物製藥等先進的治療方法至關重要。這些治療旨在減緩疾病的進展並改善患者的生活品質。這些治療方法的應用範圍廣泛，包括醫院、診所和腎臟科中心。最終用途範圍包括優先考慮創新治療策略的醫療保健提供者、製藥公司和研究機構。關鍵的成長要素包括慢性腎臟病盛行率的上升、認知的提高以及診斷技術的進步。 FSGS 的日益普及正在推動研究和開發，為藥物發現、個人化醫療和微創治療提供了充滿希望的機會。用於早期檢測的生物標記研究和用於開發標靶治療的基因研究等領域提供了巨大的商機。然而，高昂的治療費用和有限的治療效果等限制已成為主要挑戰。罕見疾病的本質阻礙了市場成長，它使臨床試驗過程變得複雜並阻礙了投資。此外，監管障礙和缺乏全面的患者登記也為市場擴張帶來了挑戰。業務成長的創新領域包括基因療法的開發和擴大我們對 FSGS病理學的理解。生物技術公司和學術機構之間的合作也可能催生新的治療解決方案。儘管市場動態複雜，但投資以患者為中心的護理模式並利用數位健康技術可以改善患者的治療結果和市場潛力。因此，這個市場的本質是利基市場，但仍在不斷發展，要求相關人員繼續適應技術進步和監管環境，同時有效滿足患者需求。

主要市場統計
基準年[2023] 161.9億美元
預計年份 [2024] 174.1億美元
預測年份 [2030] 274.5億美元
複合年成長率（%） 7.83%

市場動態：快速發展的局部節段性腎小球硬化症市場的關鍵市場洞察

供需的動態交互作用正在改變局部節段性腎絲球硬化症市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 由於遺傳和非遺傳因素導致 FSGS 病例增加
    • 人們對腎臟疾病和 FSGS 治療的認知不斷提高
    • 透過線上藥局增加 FSGS 治療的可用性
  • 市場限制因素
    • 治療費用上漲且報銷有限
  • 市場機會
    • 持續研究並開發推出 FSGS 療法的新劑型
    • 政府對 FSGS 治療和藥物的有利核准
  • 市場挑戰
    • 對 FSGS 治療的免疫抑制和副作用的擔憂

波特的五力：駕馭局部節段性腎絲球硬化症市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解局部節段性腎絲球硬化症市場的外部影響

外部宏觀環境因素在塑造局部節段性腎絲球硬化症市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解局部節段性腎絲球硬化症市場的競爭格局

對局部節段性腎絲球硬化症市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣局部節段性腎絲球硬化症市場供應商的績效評估

FPNV定位矩陣是評估局部節段性腎絲球硬化症市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了局部節段性腎小球硬化症市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對局部節段性腎小球硬化症市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於遺傳和非遺傳因素導致 FSGS 病例增加
      • 人們對腎臟疾病和 FSGS 治療的認知不斷提高
      • 透過線上藥局可得性
    • 抑制因素
      • 治療費用高，治療報銷有限。
    • 機會
      • 持續研發推出針對 FSGS 的新藥物治療方案
      • 政府對 FSGS 藥物和療法的有利核准
    • 任務
      • 對 FSGS 治療的免疫抑制和副作用的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章依藥物類別分類的局部節段性腎絲球硬化症市場

  • 血管收縮素受體阻斷劑
  • 血管張力素轉化酵素抑制劑
  • 皮質類固醇
  • 利尿劑

第7章局部節段性腎絲球硬化症市場：依階段

  • 基本的
  • 中學

第8章局部節段性腎絲球硬化症市場：依分銷管道

  • 離線
  • 線上

第 9 章 局部節段性腎絲球硬化症市場：依最終用戶分類

  • 門診手術中心
  • 家庭護理設置
  • 醫院/診所

第10章美洲局部節段腎絲球硬化市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太區域性節段性腎絲球硬化市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲局部節段性腎絲球硬化市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alkem Laboratories Ltd.
  • Cipla Ltd.
  • CMG Biotech Pvt. Ltd.
  • Dr Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • FDC Ltd.
  • Fresenius Kabi
  • Glenmark Pharmaceuticals Ltd.
  • GSK PLC
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Mankind Pharma Ltd.
  • Medley Pharmaceuticals Ltd.
  • Micro Labs Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Sunij Pharma Pvt Ltd.
  • Teva Pharmaceutical industries Ltd.
  • USV Ltd.
  • Viatris
  • ZEE Laboratories Limited
  • Zydus Healthcare Limited
Product Code: MRR-C002B1C994EF

The Focal Segmental Glomerulosclerosis Market was valued at USD 16.19 billion in 2023, expected to reach USD 17.41 billion in 2024, and is projected to grow at a CAGR of 7.83%, to USD 27.45 billion by 2030.

Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disorder characterized by scarring in parts of the glomeruli, leading to significant impairment in kidney function. The market scope and definition revolve around the pharmaceutical and healthcare sectors, where there's a critical necessity for advanced therapeutic approaches such as immunosuppressants, ACE inhibitors, and emerging biologics. These treatments aim to slow disease progression and improve quality of life for patients. The application of these treatments spans across hospitals, clinics, and specialty nephrology centers. The end-use scope involves healthcare providers, pharmaceutical companies, and research institutions prioritizing innovative treatment strategies. Key growth influencers include rising incidence rates of chronic kidney diseases, increased awareness, and advancements in diagnostic technologies. The growing prevalence of FSGS drives research and development, leading to promising opportunities in drug discovery, personalized medicine, and minimally invasive therapies. Areas like biomarker research for early detection and genetic studies for developing targeted therapies offer significant business opportunities. However, limitations such as high treatment costs and limited therapeutic efficacy pose significant challenges. The market growth is hampered by the rare nature of the disease, which complicates clinical trial processes and reduces investment incentives. Additionally, regulatory hurdles and lack of comprehensive patient registries challenge market expansion. Innovative areas for business growth include developing gene therapies and expanding the understanding of FSGS pathophysiology. Collaborations between biotech firms and academic institutions can also foster novel treatment solutions. Despite the complex market dynamics, investing in patient-centric care models and leveraging digital health technologies can enhance patient outcomes and market potential. Consequently, the nature of this market remains niche yet evolving, requiring stakeholders to stay adaptive to technological advancements and regulatory landscapes while addressing patient needs effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 16.19 billion
Estimated Year [2024] USD 17.41 billion
Forecast Year [2030] USD 27.45 billion
CAGR (%) 7.83%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Focal Segmental Glomerulosclerosis Market

The Focal Segmental Glomerulosclerosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing cases of FSGS due to genetic and non-genetic factors
    • Rising awareness about kidney disease and FSGS treatment
    • Increasing availability of FSGS medications through online pharmacies
  • Market Restraints
    • High cost and limited reimbursement available for treatment
  • Market Opportunities
    • Ongoing R&D in introducing new drug formulations for FSGS
    • Favorable government approvals for FSGS drugs and medications
  • Market Challenges
    • Concerns associated with immunosuppression and side effects of FSGS drugs

Porter's Five Forces: A Strategic Tool for Navigating the Focal Segmental Glomerulosclerosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Focal Segmental Glomerulosclerosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Focal Segmental Glomerulosclerosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Focal Segmental Glomerulosclerosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Focal Segmental Glomerulosclerosis Market

A detailed market share analysis in the Focal Segmental Glomerulosclerosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Focal Segmental Glomerulosclerosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Focal Segmental Glomerulosclerosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Focal Segmental Glomerulosclerosis Market

A strategic analysis of the Focal Segmental Glomerulosclerosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Focal Segmental Glomerulosclerosis Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Cipla Ltd., CMG Biotech Pvt. Ltd., Dr Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, FDC Ltd., Fresenius Kabi, Glenmark Pharmaceuticals Ltd., GSK PLC, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Lupin Ltd., Mankind Pharma Ltd., Medley Pharmaceuticals Ltd., Micro Labs Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Sunij Pharma Pvt Ltd., Teva Pharmaceutical industries Ltd., USV Ltd., Viatris, ZEE Laboratories Limited, and Zydus Healthcare Limited.

Market Segmentation & Coverage

This research report categorizes the Focal Segmental Glomerulosclerosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Angiotensin Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Corticosteroids, and Diuretics.
  • Based on Stage, market is studied across Primary and Secondary.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Homecare Settings, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing cases of FSGS due to genetic and non-genetic factors
      • 5.1.1.2. Rising awareness about kidney disease and FSGS treatment
      • 5.1.1.3. Increasing availability of FSGS medications through online pharmacies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and limited reimbursement available for treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D in introducing new drug formulations for FSGS
      • 5.1.3.2. Favorable government approvals for FSGS drugs and medications
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with immunosuppression and side effects of FSGS drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Focal Segmental Glomerulosclerosis Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Angiotensin Receptor Blockers
  • 6.3. Angiotensin-Converting Enzyme Inhibitors
  • 6.4. Corticosteroids
  • 6.5. Diuretics

7. Focal Segmental Glomerulosclerosis Market, by Stage

  • 7.1. Introduction
  • 7.2. Primary
  • 7.3. Secondary

8. Focal Segmental Glomerulosclerosis Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Focal Segmental Glomerulosclerosis Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Homecare Settings
  • 9.4. Hospitals & Clinics

10. Americas Focal Segmental Glomerulosclerosis Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Focal Segmental Glomerulosclerosis Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Focal Segmental Glomerulosclerosis Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alkem Laboratories Ltd.
  • 2. Cipla Ltd.
  • 3. CMG Biotech Pvt. Ltd.
  • 4. Dr Reddy's Laboratories Ltd.
  • 5. F. Hoffmann-La Roche AG
  • 6. FDC Ltd.
  • 7. Fresenius Kabi
  • 8. Glenmark Pharmaceuticals Ltd.
  • 9. GSK PLC
  • 10. Hikma Pharmaceuticals PLC
  • 11. Intas Pharmaceuticals Ltd.
  • 12. Lupin Ltd.
  • 13. Mankind Pharma Ltd.
  • 14. Medley Pharmaceuticals Ltd.
  • 15. Micro Labs Ltd.
  • 16. Novartis AG
  • 17. Pfizer, Inc.
  • 18. Sanofi S.A.
  • 19. Sun Pharmaceutical Industries Ltd.
  • 20. Sunij Pharma Pvt Ltd.
  • 21. Teva Pharmaceutical industries Ltd.
  • 22. USV Ltd.
  • 23. Viatris
  • 24. ZEE Laboratories Limited
  • 25. Zydus Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET RESEARCH PROCESS
  • FIGURE 2. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2023